JMP Securities analyst Jason Butler reiterated a Buy rating on Cormedix (CRMD – Research Report) today and set a price target of $19.00. Jason Butler has given his Buy rating
JMP Securities analyst Jason Butler reiterated a Buy rating on Cormedix (CRMD – Research Report) today and set a price target of $19.00. Jason Butler has given his Buy rating
CorMedix (CRMD) highlights key policy changes from CMS that benefit hemodialysis patients. Yesterday, the Centers for Medicare & Medicaid Services, CMS, and the Center for Medicare and Medicaid Innovation, CMMI,
Cormedix ( ($CRMD) ) has shared an update. CorMedix Inc. stockholders approved several key proposals at their annual meeting, including a plan amendment to increase shares under the 2019 Omnibus
Truist Financial analyst Les Sulewski assigned a Buy rating to the stock today. The company’s shares closed yesterday at $10.05. Sulewski covers the Healthcare sector, focusing on stocks such as
In a report released yesterday, Gregory Renza from RBC Capital maintained a Buy rating on Cormedix (CRMD – Research Report), with a price target of $11.00. The company’s shares closed